Dr Nathalie Jacque

Locationsموقعنا

CMC Hospital – DHCC 2

Languagesاللغات

English French

Bio

السيرة

Dr Nathalie Jacque is a consultant hematologist in CMC Dubai. She received her French Board of Hematology in 2011 after 6 years of residency in Paris.

After her graduation, she began a research program at Cochin Institute working on treatment of acute leukemia. She obtained her PhD in Hematology and Oncology from Paris Sorbonne University in 2015.

At the same time, she was a consultant hematologist in Pitié Salpêtrière Hospital in Paris. She was first in charge of an intensive care unit (chemotherapy for acute leukemia, autologous and allogeneic stem cell transplantation) and then of the daily care hospital (treatments of lymphomas, myelomas, myelodysplastic syndromes, acute leukemias; post allogeneic SCT consultations; Immunoglobuline and blood transfusions; iron therapy).

She is a member of the Lymphoma study association (LYSA), Francophone Myeloma Intergroup (IFM), French society of bone marrow transplant and cellular therapy (SFGM-TC).

Treatments

العلاجات

Diagnosis and treatment of all hematological disorders either benign or malignant: anemia, cytopenias, immunodeficiency, myeloid and lymphoid cancers.
Chemotherapy and oral therapy, iron and immunoglobuline perfusions and blood transfusion.
Bone marrow biopsy and aspirations, lumbar puncture

Education

التعليم

Ecole Doctorale Hématologie Oncogenèse Biothérapies Paris Sorbonne University, PHD 2015

Doctor of Medecine (MD), Paris VI University, Hematology Specialty. 2011

Master of Science, Paris V, « Cellular biology, physiology, pathology, 2010

Medical Residency, Paris, 2005-2011

Publications

Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. Forgeard N, Baron M, Caron J, Boccon-Gibod C, Krzisch D, Guedes N, Morel V, Jacque N, Ouzegdouh M, Choquet S, Bravetti C, Nguyen-Khac F, Chapiro E, Leblond V, Roos-Weil D. Haematologica. 2022
CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network. Alcantara M, Houillier C, Blonski M, Rubio MT, Willems L, Waultier Rascalou A, Le Garff-Tavernier M, Maloum K, Bravetti CM, Souchet L, Roos-Weil D, Morel V, Uzunov M, Metz C, Dhib-Charfi M, Nguyen S, Shor N, Psimaras D, Weiss N, Jacque N, Solorzano S, Gauthier N, Le Cann M, Norol F, Soussain C, Choquet S. Blood. 2021
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Garnache-Ottou F, Vidal C, Biichlé S, …, Jacques N …, Deconinck E. Blood Adv. 2019
Chronic lymphocytic leukemia Jacque N, Leblond V. Presse Med. 2019
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J. Leukemia. 2018
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Sci Adv. 2015
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Thiago TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Blood. 2015
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia. Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decroocq J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J. Cell Rep. 2015
Targeting glutamine uptake in AML. Jacque N, Bouscary D. Oncoscience. 2014
Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia. Jacque N, Nguyen S, Golmard JL, Uzunov M, Garnier A, Leblond V, Vernant JP, Bories D, Dhédin N. Bone Marrow Transplant. 2015
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Leukemia. 2012
The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Br J Haematol. 2012

Bio

السيرة

Treatments

العلاجات

Education

التعليم

Publications

Related services

الخدمات ذات الصلة

Oncology & Hematology

About Us

Services

Patient Care